Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 14/20 | 1.00 |
| ▸ | SLC16A7 | O60669 | 1/20 | 1.00 |
| ▸ | SLC16A8 | O95907 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Msc-4381 SCHEMBL22116621 | 1.00 | SLC16A3 (1.00) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL22116778 | 0.95 | SLC16A3 (0.90) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL22116703 | 0.94 | SLC16A3 (0.89) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL22116501 | 0.91 | SLC16A3 (0.84) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL22116679 | 0.91 | SLC16A3 (1.00) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL30188226 | 0.91 | SLC16A3 (1.00) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL30188311 | 0.88 | SLC16A3 (0.94) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL22116779 | 0.88 | SLC16A3 (0.94) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 | |
| SCHEMBL30182486 | 0.87 | SLC16A3 (0.77) | SLC16A3SLC16A7SLC16A8HTR5APOLB | |
| SCHEMBL24109639 | 0.87 | SLC16A3 (0.77) | SLC16A3SLC16A7SLC16A8HTR5AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121668166-A | SLC16A3 inhibitor based on iron death regulation and application thereof in lung adenocarcinoma | 中国人民解放军总医院第一医学中心 | 2026-03-17 | — | — | CN | disclosed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024161041-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | XENIOM GMBH (DE) | 2024-08-08 | — | — | WO | disclosed |